Skip to main content
SpringerLink
Log in

Ovarian Cancer: Primary Advanced and Recurrent Disease

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3317 Accesses

Abstract

Approximately 70% of patients affected by epithelial ovarian cancer (EOC) are diagnosed with FIGO stage III–IV disease and 50–70% of them will develop a recurrence, after a median progression-free survival (PFS) of approximately 18 months. The 5-year survival for stage III and IV ranges from 39% to 17%, respectively. Treatment options for primary advanced and recurrent disease comprehend surgery (primary cytoreductive surgery or interval cytoreductive surgery after neoadjuvant chemotherapy for primary advanced disease and secondary cytoreductive surgery for recurrent disease) and systemic therapy (standard and novel chemotherapeutic agents and biological agents).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. https://doi.org/10.3322/caac.20073.

    Article  PubMed  Google Scholar 

  2. Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8 Suppl 1:S22–30.

    PubMed  Google Scholar 

  3. Zeng J, Huang H, Shan Y, Li Y, Jin Y, Pan L. The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery. J Cancer. 2017;8(17):3410–5. https://doi.org/10.7150/jca.21362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ezzati M, Abdullah A, Shariftabrizi A, Hou J, Kopf M, Stedman JK, et al. Recent advancements in prognostic factors of epithelial ovarian carcinoma. Int Scholar Res Not. 2014;2014:1–10. https://doi.org/10.1155/2014/953509.

    Article  Google Scholar 

  5. Prat J, Committee F. International Journal of Gynecology and Obstetrics Staging classification for cancer of the ovary, fallopian tube, and peritoneum ☆. Int J Gynecol Obstet. 2013;124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001.

    Article  Google Scholar 

  6. Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, Pignata S. First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 2010; https://doi.org/10.1586/ERA.09.167.

  7. Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013;121(6):1226–34. https://doi.org/10.1097/AOG.0b013e3182922a17.

    Article  CAS  PubMed  Google Scholar 

  8. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(SUPPL. 8):7–12. https://doi.org/10.1093/annonc/mdi961.

    Article  Google Scholar 

  9. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–90. https://doi.org/10.1016/j.ygyno.2006.06.028.

    Article  PubMed  Google Scholar 

  10. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVA). Gynecol Oncol. 2007;106(1):69–74. https://doi.org/10.1016/j.ygyno.2007.02.026.

    Article  PubMed  Google Scholar 

  11. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59. https://doi.org/10.1200/JCO.2002.20.5.1248.

    Article  PubMed  Google Scholar 

  12. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol. 2007; https://doi.org/10.1200/JCO.2007.11.0932.

  13. Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology (Williston Park, N.Y.). 2011;25(10):928–34.

    PubMed  Google Scholar 

  14. Bristow BRE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Effect maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era. J Clin Oncol. 2008;20(5):1248–59. https://doi.org/10.1200/JCO.2002.20.5.1248.

    Article  Google Scholar 

  15. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. In: Elattar A, editor. Cochrane database of systematic reviews. Chichester, UK: Wiley; 2011. p. CD007565. https://doi.org/10.1002/14651858.CD007565.pub2.

    Chapter  Google Scholar 

  16. Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA. Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol. 2009;114(1):32–6. https://doi.org/10.1016/j.ygyno.2009.03.020.

    Article  PubMed  Google Scholar 

  17. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97(8):560–6. https://doi.org/10.1093/jnci/dji102.

    Article  PubMed  Google Scholar 

  18. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. Br J Cancer. 2007;96(12):1817–22. https://doi.org/10.1038/sj.bjc.6603803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. 2005;99(2):427–31. https://doi.org/10.1016/j.ygyno.2005.06.051.

    Article  PubMed  Google Scholar 

  20. Karam A, Ledermann JA, Kim J-W, Sehouli J, Lu K, Gourley C, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions. Ann Oncol. 2017;28(4):711–7. https://doi.org/10.1093/annonc/mdx011.

    Article  CAS  PubMed  Google Scholar 

  21. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. https://doi.org/10.1016/j.ygyno.2009.03.018.

    Article  PubMed  Google Scholar 

  22. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2012;8:CD005343. https://doi.org/10.1002/14651858.CD005343.pub3.

    Article  Google Scholar 

  23. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57. https://doi.org/10.1016/S0140-6736(14)62223-6.

    Article  PubMed  Google Scholar 

  24. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. https://doi.org/10.1056/NEJMoa0908806.

    Article  CAS  PubMed  Google Scholar 

  25. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6. https://doi.org/10.1016/j.ygyno.2006.06.025.

    Article  CAS  PubMed  Google Scholar 

  26. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(28):3460–73. https://doi.org/10.1200/JCO.2016.68.6907.

    Article  PubMed  Google Scholar 

  27. Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135(2):223–30. https://doi.org/10.1016/j.ygyno.2014.09.002.

    Article  CAS  PubMed  Google Scholar 

  28. Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. Int J Gynecol Cancer. 2011;21(4):750–5. https://doi.org/10.1097/IGC.0b013e31821b2568.

    Article  PubMed  Google Scholar 

  29. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JPA. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006;98(22):1655–63. https://doi.org/10.1093/jnci/djj443.

    Article  CAS  PubMed  Google Scholar 

  30. Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic cooperative oncology group (HeCOG) study. Eur J Cancer. 2008;44(15):2169–77. https://doi.org/10.1016/j.ejca.2008.06.035.

    Article  CAS  PubMed  Google Scholar 

  31. Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, et al. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer. 2010;46(16):2905–12. https://doi.org/10.1016/j.ejca.2010.06.124.

    Article  CAS  PubMed  Google Scholar 

  32. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J Clin Oncol. 2009;27(9):1419–25. https://doi.org/10.1200/JCO.2008.19.1684.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. du Bois A, Herrstedt J, Hardy-Bessard A-C, Müller H-H, Harter P, Kristensen G, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–9. https://doi.org/10.1200/JCO.2009.27.4696.

    Article  CAS  PubMed  Google Scholar 

  34. Du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study G. J Clin Oncol. 2006;24(7):1127–35. https://doi.org/10.1200/JCO.2005.03.2938.

    Article  CAS  PubMed  Google Scholar 

  35. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010;102(20):1547–56. https://doi.org/10.1093/jnci/djq362.

    Article  CAS  PubMed  Google Scholar 

  36. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6. https://doi.org/10.1016/S1470-2045(13)70363-2.

    Article  CAS  PubMed  Google Scholar 

  37. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–8. https://doi.org/10.1016/S0140-6736(09)61157-0.

  38. Seagle B-LL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecol Oncol. 2017;145(1):9–14. https://doi.org/10.1016/j.ygyno.2017.02.014.

    Article  CAS  PubMed  Google Scholar 

  39. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396–405. https://doi.org/10.1016/S1470-2045(14)70049-X.

  40. Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, et al. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. ESMO Open. 2016;1(6):e000117. https://doi.org/10.1136/esmoopen-2016-000117.

    Article  PubMed  Google Scholar 

  41. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. https://doi.org/10.1056/NEJMoa1104390.

    Article  CAS  PubMed  Google Scholar 

  42. Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., … ICON7 Investigators. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 365(26), 2484–2496. https://doi.org/10.1056/NEJMoa1103799.

  43. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al.; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 2006:354(1);34–43. https://doi.org/10.1056/NEJMoa052985.

  44. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. In: Jaaback K, editor. Cochrane database of systematic reviews. Chichester, UK: Wiley; 2016. https://doi.org/10.1002/14651858.CD005340.pub4.

    Chapter  Google Scholar 

  45. Davidson SA, Rubin SC, Markman M, Jones WB, Hakes TB, Reichman B, et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol. 1991;41(2):101–6.

    Article  CAS  PubMed  Google Scholar 

  46. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100(1):27–32. https://doi.org/10.1016/j.ygyno.2005.11.013.

    Article  PubMed  Google Scholar 

  47. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006; https://doi.org/10.1097/01.AOG.0000220516.34053.48.

  48. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol. 1997;15(1):193–8. https://doi.org/10.1200/JCO.1997.15.1.193.

    Article  CAS  PubMed  Google Scholar 

  49. Bergamini A, Pisano C, Di Napoli M, Arenare L, Della Pepa C, Tambaro R, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2017;144(1):72–6. https://doi.org/10.1016/j.ygyno.2016.10.023.

    Article  CAS  PubMed  Google Scholar 

  50. du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-U). Gynecol Oncol. 2007;107(3):518–25. https://doi.org/10.1016/j.ygyno.2007.08.008.

    Article  CAS  PubMed  Google Scholar 

  51. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9. https://doi.org/10.1200/JCO.2009.25.7519.

    Article  CAS  PubMed  Google Scholar 

  52. Parmar, M. K. B., Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J.-F., Kristensen, G. B., … ICON and AGO Collaborators. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (London, England), 361(9375), 2099–2106.

    Google Scholar 

  53. Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–91. https://doi.org/10.1038/bjc.2012.307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pfisterer J, Plante M, Vergote I, Du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707. https://doi.org/10.1200/JCO.2006.06.0913.

    Article  CAS  PubMed  Google Scholar 

  55. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–14. https://doi.org/10.1200/JCO.2009.25.4037.

    Article  CAS  PubMed  Google Scholar 

  56. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–55. https://doi.org/10.1200/JCO.2009.21.8909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 1995;72(4):1016–9. https://doi.org/10.1038/bjc.1995.453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–22. https://doi.org/10.1200/JCO.2001.19.14.3312.

    Article  CAS  PubMed  Google Scholar 

  59. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. https://doi.org/10.1200/JCO.2007.13.6606.

    Article  CAS  PubMed  Google Scholar 

  60. Bruchim I, Ben-Harim Z, Piura E, Haran G, Fishman A. Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. J Chemother. 2016;28(2):129–34. https://doi.org/10.1080/1120009X.2015.1115195.

    Article  CAS  PubMed  Google Scholar 

  61. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 1998;16(2):405–10. https://doi.org/10.1200/JCO.1998.16.2.405.

    Article  CAS  PubMed  Google Scholar 

  62. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group. J Clin Oncol. 2009;27(16):2686–91. https://doi.org/10.1200/JCO.2008.19.2963.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45. https://doi.org/10.1200/JCO.2012.42.0505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. https://doi.org/10.1200/JCO.2013.51.4489.

    Article  CAS  PubMed  Google Scholar 

  65. Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–16. https://doi.org/10.1200/JCO.2013.51.4240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2016; https://doi.org/10.1016/j.bpobgyn.2016.12.001.

  67. Du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–81. https://doi.org/10.1200/JCO.2014.55.7348.

    Article  PubMed  Google Scholar 

  68. Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561–8. https://doi.org/10.1016/S1470-2045(15)70115-4.

    Article  CAS  PubMed  Google Scholar 

  69. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601–6. https://doi.org/10.1200/JCO.2009.23.2777.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016a;387(10023):1066–74. https://doi.org/10.1016/S0140-6736(15)01167-8.

    Article  CAS  PubMed  Google Scholar 

  71. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJS, et al. Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. ASCO Ann Meet. 2016b;17(11)., Abstract number 5501. https://doi.org/10.1016/S1470-2045(16)30376-X.

  72. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14. https://doi.org/10.1016/S1470-2045(14)70391-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17(1):78–89. https://doi.org/10.1016/S1470-2045(15)00366-6.

    Article  CAS  PubMed  Google Scholar 

  74. Bono M, Fanale D, Incorvaia L, et al. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge [published online ahead of print, 2021 Aug 6]. ESMO Open. 2021;6(4):100235. https://doi.org/10.1016/j.esmoop.2021.100235.

  75. Gori S, Barberis M, Bella MA, et al. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Crit Rev Oncol Hematol. 2019;140:67–72. https://doi.org/10.1016/j.critrevonc.2019.05.012.

  76. Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBIOC-SIF italian scientific societies [published online ahead of print, 2021 Aug 6]. Crit Rev Oncol Hematol. 2021;103436. https://doi.org/10.1016/j.critrevonc.2021.103436.

  77. Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016;12(12):1439–56. https://doi.org/10.2217/fon-2016-0002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol. 2015; https://doi.org/10.1093/annonc/mdv250.

  79. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The α folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;121(2):225–33. https://doi.org/10.1067/mtc.2001.111176.

    Article  CAS  PubMed  Google Scholar 

  80. Kalli KR, Oberg AL, Keeney GL, Christianson TJH, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–26. https://doi.org/10.1016/j.ygyno.2007.11.020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia (United States). 2016;18(12):775–84. https://doi.org/10.1016/j.neo.2016.11.002.

    Article  CAS  Google Scholar 

  82. Jelovac D, Armstrong K. Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des. 2012;18(25):3812–5. https://doi.org/10.2174/138161212802002698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Moore KN, Martin LP, O’Malley DM, Matulonis UA, Konner JA, Vergote I, et al. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Fut Oncol (London, England). 2017;14(2):123–36. https://doi.org/10.2217/fon-2017-0379.

    Article  CAS  Google Scholar 

  84. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31(35):4400–6. https://doi.org/10.1200/JCO.2013.49.7685.

    Article  CAS  PubMed  Google Scholar 

  85. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88(1):144–53.

    Article  CAS  PubMed  Google Scholar 

  86. Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109(4):685–91. https://doi.org/10.1002/cncr.22447.

    Article  PubMed  Google Scholar 

  87. Scarabelli C, Gallo A, Visentin MC, Canzonieri V, Carbone A, Zarrelli A. Systematic pelvic and Para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer. 1997;7(1):18–26.

    Article  CAS  PubMed  Google Scholar 

  88. Harter P, Du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10. https://doi.org/10.1245/s10434-006-9058-0.

    Article  PubMed  Google Scholar 

  89. Ushijima K. Treatment for recurrent ovarian cancer—at first relapse. J Oncol. 2010;2010:1–7. https://doi.org/10.1155/2010/497429.

    Article  CAS  Google Scholar 

  90. Pujade-Lauraine E, Combe P. Recurrent ovarian cancer. Ann Oncol. 2016;27(suppl 1):i63–5. https://doi.org/10.1093/annonc/mdw079.

    Article  PubMed  Google Scholar 

  91. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs. 2010; https://doi.org/10.1155/2010/207084.

  92. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48. https://doi.org/10.1093/annonc/mdq352.

  93. Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015;26(5):914–20. https://doi.org/10.1093/annonc/mdv071.

  94. Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2015;19(7):1–524. https://doi.org/10.3310/hta19070.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy

    Domenica Lorusso

  2. Università Cattolica del Sacro Cuore, Rome, Italy

    Giuseppa Maltese

  3. Fondazione IRCCS Istituto 21Nazionale dei Tumori, Milan, Italy

    Ilaria Sabatucci

  4. IRCCS National Cancer Institute, Department of Gynecologic Oncology, Milan, Italy

    Stefano Lepori

  5. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

Authors
  1. Domenica Lorusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppa Maltese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorena Incorvaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilaria Sabatucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefano Lepori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenica Lorusso .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lorusso, D., Maltese, G., Incorvaia, L., Sabatucci, I., Lepori, S. (2021). Ovarian Cancer: Primary Advanced and Recurrent Disease. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_52

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_52

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation